<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4572">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697654</url>
  </required_header>
  <id_info>
    <org_study_id>TLC19A1001</org_study_id>
    <nct_id>NCT04697654</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Liposome Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Liposome Company</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability, and&#xD;
      PK of single ascending doses of inhaled TLC19 in healthy volunteer subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability,&#xD;
      and PK of single ascending doses of inhaled TLC19 (Hydroxychloroquine Liposome Inhalation&#xD;
      Suspension) in healthy volunteer subjects. Three dose levels will be assessed in sequential&#xD;
      cohorts, with 2 mL, 4 mL, and 6 mL. Total of approximately 30 subjects will be randomized in&#xD;
      the study in 3 cohorts. Subjects will be enrolled and randomized to receiving either TLC19 or&#xD;
      TLC 19 Vehicle.&#xD;
&#xD;
      Drug Administration: Blinded study medication will be administered through inhalation via a&#xD;
      portable vibration mesh nebulizer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>0-28 Days</time_frame>
    <description>To evaluate the severity, seriousness, outcome, and action taken of AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum blood concentration</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum blood concentration</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood concentration-time curve</measure>
    <time_frame>0-168 hours</time_frame>
    <description>AUC0-last</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>TLC19 (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TLC19 2ml single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC19 (medium dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TLC19 4ml single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC19 (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TLC19 6ml single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC19 Vehicle (low dose)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TLC19 Vehicle 2ml single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC19 Vehicle (medium dose)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TLC19 Vehicle 4ml single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC19 Vehicle (high dose)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TLC19 Vehicle 6ml single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLC19</intervention_name>
    <description>Hydroxychloroquine Liposome Inhalation Suspension</description>
    <arm_group_label>TLC19 (high dose)</arm_group_label>
    <arm_group_label>TLC19 (low dose)</arm_group_label>
    <arm_group_label>TLC19 (medium dose)</arm_group_label>
    <other_name>TLC19 (Hydroxychloroquine Liposome Inhalation Suspension)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLC19 Vehicle</intervention_name>
    <description>Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)</description>
    <arm_group_label>TLC19 Vehicle (high dose)</arm_group_label>
    <arm_group_label>TLC19 Vehicle (low dose)</arm_group_label>
    <arm_group_label>TLC19 Vehicle (medium dose)</arm_group_label>
    <other_name>TLC19 Vehicle (same formulation as TLC19 but without the active ingredient)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 18 to 65 years of age&#xD;
&#xD;
          2. Body mass index (BMI) 18.0 to 30.0 kg/m2.&#xD;
&#xD;
          3. Never-smoker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body weight &lt;50 kg&#xD;
&#xD;
          2. Donation of blood (450 mL) or blood loss within 3 months prior to study&#xD;
&#xD;
          3. Contraindication, allergy, or hypersensitivity to hydroxychloroquine or chloroquine or&#xD;
             other 4 aminoquinolines&#xD;
&#xD;
          4. Use of any prescription or OTC medications or herbal supplements within 2 weeks (or&#xD;
             5half-lives if longer) prior to study&#xD;
&#xD;
          5. Use of any investigational product/medical device within 30 days or 5 half-lives prior&#xD;
             to study, or participation in â‰¥4 investigational drug studies within 1 year prior to&#xD;
             study&#xD;
&#xD;
          6. History or presence of any of the following conditions:&#xD;
&#xD;
               -  Autoimmune or rheumatoid inflammatory disease&#xD;
&#xD;
               -  Cardiac disorders&#xD;
&#xD;
               -  Lung disease, prior intubation, or requiring use of an inhaler&#xD;
&#xD;
               -  Liver cirrhosis or Child-Pugh class C&#xD;
&#xD;
               -  Retinopathy or maculopathy&#xD;
&#xD;
               -  Neuromuscular diseases&#xD;
&#xD;
               -  Glucose-6 phosphate dehydrogenase deficiency&#xD;
&#xD;
               -  Hematologic malignancy&#xD;
&#xD;
               -  Chronic kidney disease or renal failure&#xD;
&#xD;
               -  Psoriasis or porphyria&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Severe allergic or anaphylactic reactions&#xD;
&#xD;
               -  Any other significant condition that would preclude participation&#xD;
&#xD;
          7. History of substance abuse or dependency in the last 12 months, or a history of&#xD;
             recreational intravenous drug use over the last 5 years&#xD;
&#xD;
          8. Fever or symptomatic viral or bacterial infection within 2 weeks prior to study&#xD;
&#xD;
          9. Any clinically significant laboratory abnormality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Brown, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Taiwan Liposome Company, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scientia Clinical Reserach, Ltd</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital Tamsui Branch</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hydroxychloroquine</keyword>
  <keyword>Inhalation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

